COAST Therapy in Advanced Solid Tumors and Prostate Cancer

The purpose of this Phase I/II study is to determine the safety and effectiveness of up to 5 study drugs used together for the treatment of solid tumor cancers. The drugs are hydroxychloroquine, metformin, sirolimus, dasatinib and nelfinavir and are given orally.

Trial Details

NCT ID

NCT05036226

Phase

PHASE1 / PHASE2

Sponsor

Medical University of South Carolina

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

Hydroxychloroquine, Metformin, Sirolimus
Hydroxychloroquine, Metformin, Sirolimus, Dasatanib
Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir
Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib

Locations (sample)

Charleston, South Carolina, United States|32.77632,-79.93275

Key Eligibility Criteria

Patient must have advanced solid tumor cancer of any type (Phase I) or advanced prostate cancer (Phase II). Prostate cancer patients must have a PS…
Tissue diagnosis documented by pathology report, or clinic note attesting to same.
Measurable / evaluable tumor by RECIST, quantitative blood biomarker, or radionuclide imaging
Voluntary, signed and dated, Institutional Review Board (IRB) approved consent form in accordance with regulatory and institutional guidelines.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →